Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021

Rhea-AI Summary

Aeglea BioTherapeutics (NASDAQ:AGLE) announced its participation in two virtual investor conferences in April 2021. The first event is the 2021 Virtual Wells Fargo Biotech Corporate Access Day on April 6 and 8, featuring CEO Anthony G. Quinn. The second is the 20th Annual Needham Virtual Healthcare Conference, taking place April 12-15, with a presentation by Quinn on April 13 at 11:00 am ET. This biotechnology company focuses on developing human enzyme therapeutics for rare metabolic diseases, including its lead product candidate, pegzilarginase.

AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021.  

Conference Details

Conference Name: 2021 Virtual Wells Fargo Biotech Corporate Access Day
Conference Date: Tuesday, April 6 and Thursday, April 8
Participants: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and chief executive officer and Michael C. Hanley, Aeglea's chief commercial officer

Conference Name: 20^th Annual Needham Virtual Healthcare Conference
Conference Date: Monday, April 12 through Thursday, April 15
Presentation Date and Time: Tuesday, April 13 at 11:00 am ET
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and chief executive officer
Webcast: https://ir.aeglea.com/events-and-presentations/  

To access the live and archived webcast, visit the Events & Presentations section of the Company's website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. A replay of the webcast will be available through the Company's website for 30 days thereafter.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria in 2020. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021-301261051.html

SOURCE Aeglea BioTherapeutics, Inc.

FAQ

What conferences is Aeglea BioTherapeutics attending in April 2021?

Aeglea BioTherapeutics will attend the 2021 Virtual Wells Fargo Biotech Corporate Access Day on April 6 and 8, and the 20th Annual Needham Virtual Healthcare Conference from April 12 to 15.

When is Aeglea BioTherapeutics presenting at the Needham Virtual Healthcare Conference?

Aeglea BioTherapeutics will present on April 13, 2021, at 11:00 am ET during the Needham Virtual Healthcare Conference.

Who is the CEO of Aeglea BioTherapeutics?

The CEO of Aeglea BioTherapeutics is Anthony G. Quinn, M.B. Ch.B., Ph.D.

What is Aeglea BioTherapeutics' lead product candidate?

Aeglea BioTherapeutics' lead product candidate is pegzilarginase, which is in a pivotal Phase 3 trial for treating Arginase 1 Deficiency.

What designations have been granted to Aeglea BioTherapeutics' products?

Pegzilarginase has received Rare Pediatric Disease and Breakthrough Therapy Designation, while AGLE-177 has also been granted Rare Pediatric Disease Designation.